Repositorio Dspace

Listar01.01. Investigación y comunicación científica por tema "Infant, Newborn"

Listar01.01. Investigación y comunicación científica por tema "Infant, Newborn"

Ordenar por:Orden:Resultados:

  • Access to unfunded vaccination and associated socioeconomic factors in a cohort of infants from a health area of the Region of Murcia (Spain). 
    Molina-Salas, Yolanda; Romera-Guirado, Francisco-José; Sánchez-Marin, M-Del-Carmen; Navarro-Guerrero, Rosario; Romera-Guirado, María-Jesús; Pérez-Martín, Jaime-Jesús (MINISTERIO DE SANIDAD Y CONSUMO, )
    OBJECTIVE: The vaccines that are not funded by the government could create some inequities among the infants, because some of them do not have as many chances to get that immunization as others. The objective of this paper ...
  • Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season 
    Núñez, Olivier; Olmedo, Carmen; Moreno-Pérez, David; Lorusso, Nicola; Fernández-Martínez, Sergio; Pastor-Villalba, Pedro-Eliseo; Gutiérrez, Ángeles; García, Marcos-Alonso; Latasa, Pello; Sancho, Rosa; Mendioroz, Jacobo; Martínez-Marcos, Montserrat; Muñoz-Platon, Enrique; García-Rivera, María-Victoria; Pérez-Martínez, Olaia; Álvarez-Gil, Rosa; Wagner, Eva-Rivas; López-González-Coviella, Nieves; Zornoza-Moreno, Matilde; Barranco-Boada, María-Isabel; Pacheco, M-del-Carmen; Álvarez-Río, Virginia; Jaume, Miguel-Fiol; Arance, Roxana-Morey; Sancho, Begoña-Adiego; Méndez-Díaz, Manuel; Batalla-Rebollo, Noa; Andreu, Cristina; Castilla, Jesús; García-Cenoz, Manuel; Fernández-Ibáñez, Ana; Huerta-Huerta, Marta; Ibáñez-Pérez, Ana-Carmen; Berradre-Saenz, Belén; Lamas, Joaquín; Hermoso, Luisa; Casado-Cobo, Susana; Galán-Cuesta, Manuel; Montenegro, Sara; Domínguez, María; Jarrin, Inmaculada; Limia, Aurora; Pastor-Barriuso, Roberto; Monge, Susana (EUR CENTRE DIS PREVENTION & CONTROL, 2025-02-06)
    BackgroundRespiratory syncytial virus (RSV) causes substantial morbidity in infants < 1 year. In October 2023, Spain recommended the monoclonal antibody nirsevimab to all children born since 1 April 2023, at birth or as ...
  • Monitoring effectiveness of nirsevimab immunization against RSV hospitalization using surveillance data: a test-negative case-control study, Spain, October 2024-March 2025 
    Campos-Mena, Sandra; Pérez-Gimeno, Gloria; Lorusso, Nicola; Álvarez-Rio, Virginia; Basile, Luca; Batalla-Rebollo, Noa; García-Comas, Luis; Andreu-Ivorra, Blanca; Pérez-Panades, Jordi; Ramos-Marin, Violeta; Castrillejo, Daniel; Fernández-Ibáñez, Ana; Rafael-de-la-Cruz-López, María-Ángeles; Núñez, Olivier; Monge, Susana (CAMBRIDGE UNIV PRESS, 2026)
    Effectiveness of nirsevimab against respiratory syncytial virus (RSV) hospitalization during the 2024/2025 season in Spain was estimated using a test-negative design (TND) and hospital-based respiratory infections surveillance ...
  • Nirsevimab Effectiveness Against Severe Respiratory Syncytial Virus Infection in the Primary Care Setting 
    López-Lacort, Mónica; Muñoz-Quiles, Cintia; Mira-Iglesias, Ainara; Xavier-López-Labrador, F; Garces-Sánchez, María; Escribano-López, Begoña; Zornoza-Moreno, Matilde; Pérez-Martín, Jaime-Jesús; Alfayate-Miguelez, Santiago; Iofrío-de-Arce, Antonio; Pastor-Villalba, Eliseo; Lluch-Rodrigo, José-Antonio; Diez-Domingo, Javier; Orrico-Sánchez, Alejandro; MEDIPRIM-Network (AMER ACAD PEDIATRICS, 2025-01-01)
    OBJECTIVES: This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTIs) in a large primary care ...
  • Strategies used to improve immunization coverage of nirsevimab in an autonomous community in Spain 
    Zornoza-Moreno, Matilde; Yelo-Cano, Jesús-Javier; Pérez-Martín, Jaime-Jesús (TAYLOR & FRANCIS LTD, 46387)
    Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections, particularly in infants under one year. In 2023, Spain became one of the first countries to implement nirsevimab, a long-acting ...
  • Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case-control study, Spain, October 2023 to March 2025 
    Núñez, Olivier; Juaneda, Juan; Martínez-Marcos, Montserrat; Muñoz-Platón, Enriqueta; Rivas-Wagner, Eva; Santiago-Pérez, María-Isolina; Álvarez-Río, Virginia; Zornoza-Moreno, Matilde; Fernández-Ibáñez, Ana; Pérez-Suárez, Gisselle; Lorono-Ortiz, Gorka; Egues, Nerea; Berradre-Saenz, Belén; Cuesta-Franco, María-de-los-Ángeles; Casado-Cobo, Susana; Domínguez-Padilla, María; Castrillejo, Daniel; Mínguez-Santiyan, Ana; Basile, Luca; Rafael-de-la-Cruz-López, María-Ángeles; Sanabria-Curbelo, Diana; Pérez-Martínez, Olaia; Rodríguez-Recio, M-Jesús; Duró-Gómez, Lourdes; Alonso-Vigil, María-del-Pilar; Méndez-Díaz, Manuel-A; Sancho, Rosa; Castilla, Jesus; Ibáñez-Pérez, Ana-Carmen; Batalla-Rebollo, Noa; Sánchez-Piorno, Lucía; López-Berrios, Ninoska; Lamas, Joaquín; Olmedo, Carmen; Monge, Susana; Pastor-Barriuso, Roberto (EUR CENTRE DIS PREVENTION & CONTROL, 2026-03-05)
    BACKGROUNDIn autumn 2023, Spain recommended nirsevimab to all infants born after 1 April 2023, as catch-up or at-birth immunisation.AIMWe estimated effectiveness of a single nirsevimab dose against respiratory syncytial ...

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta